# US 2021/0275626 A1 · Use of an abc transporter peptide inhibitor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275626 A1
- Document ID: US20210275626A1
- Status: Published application
- Kind: A1
- Application number: 17/324,053
- Filed: 2021-05-18
- Published: 2021-09-09
- Earliest claimed: 2020-05-18
- Assignees: Hunan University of Science and Engineering
- Applicants: Hunan University of Science and Engineering
- Inventors: Xiaofang LUO; Zuodong QIN; Meifeng WANG; Dongfang TANG
- Web page: https://patentgrep.com/patent/US20210275626A1

## CPC

- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/365: Lactones
- A61K 31/475: having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine (vincamine A61K31/4375)
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 33/243: Platinum; Compounds thereof
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed herein is a use of an adenosine triphosphate (ATP) binding cassette (ABC) transporter peptide inhibitor HX-12C. This disclosure also discloses a method of treating a tumor with multidrug resistance mediated by the ABC transporter using a combination of the peptide HX-12C shown in SEQ ID NO: 1 and an ABC transporter substrate chemotherapeutic drug. Moreover, this disclosure also provides a composition for treating a tumor with multidrug resistance mediated by an ABC transporter, consisting of the peptide HX-12C shown in SEQ ID NO: 1 and an ABC transporter substrate chemotherapeutic drug.

## Claims

### Claim 1

A method of treating a tumor with multidrug resistance in a subject in need thereof, comprising:
administering a peptide HX-12C shown in SEQ ID NO: 1 to the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the multidrug resistance is mediated by an adenosine triphosphate (ATP)-binding cassette (ABC) transporter.

### Claim 3 (depends on 2)

The method of claim 2, wherein the ABC transporter is ATP-binding cassette subfamily B member 1 (ABCB1) or ATP-binding cassette subfamily C member 1 (ABCC1).

### Claim 4

A method of treating a tumor with multidrug resistance mediated by an ABC transporter in a subject in need thereof, comprising:
administering a combination of a peptide HX-12C shown in SEQ ID NO: 1 and an ABC transporter substrate chemotherapeutic drug to the subject.

### Claim 5 (depends on 4)

The method of claim 4, wherein the ABC transporter is ABCB1 or ABCC1.

### Claim 6 (depends on 5)

The method of claim 5, wherein when the ABC transporter is the ABCB1, the ABC transporter substrate chemotherapeutic drug is selected from the group consisting of taxanes, vinca alkaloids, anthracyclines, epipodophyllotoxins, tyrosine kinase inhibitors and antitumor antibiotics; and when the ABC transporter is the ABCC1, the ABC transporter substrate chemotherapeutic drug is selected from the group consisting of vinca alkaloids, anthracyclines, epipodophyllotoxins and tyrosine kinase inhibitors.

### Claim 7 (depends on 6)

The method of claim 6, wherein when the ABC transporter is the ABCB1, the ABC transporter substrate chemotherapeutic drug is selected from the group consisting of paclitaxel, docetaxel, vinblastine, vincristine, adriamycin, daunorubicin, etoposide, teniposide, imatinib, nilotinib, erlotinib dactinomycin D and a combination thereof; and when the ABC transporter is the ABCC1, the ABC transporter substrate chemotherapeutic drug is selected from the group consisting of anthracyclines, vinca alkaloids, epipodophyllotoxins, camptothecin, methotrexate, saquinavir, mitoxantrone, imatinib and a combination thereof.

### Claim 8

A pharmaceutical composition for treating a tumor with multidrug resistance mediated by an ABC transporter, consisting of:
a peptide HX-12C shown in SEQ ID NO: 1 and an ABC transporter substrate chemotherapeutic drug.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein when the ABC transporter is ABCB1, the ABC transporter substrate chemotherapeutic drug is selected from the group consisting of a taxane, a vinca alkaloid, an anthracycline, an epipodophyllotoxin, a tyrosine kinase inhibitor and an antitumor antibiotic; and when the ABC transporter is ABCC1, the ABC transporter substrate chemotherapeutic drug is selected from the group consisting of a vinca alkaloid, an anthracycline, an epipodophyllotoxin and tyrosine kinase inhibitor.

### Claim 10 (depends on 9)

The pharmaceutical composition of claim 9, wherein when the ABC transporter is ABCB1, the ABC transporter substrate chemotherapeutic drug is selected from the group consisting of paclitaxel, docetaxel, vinblastine, vincristine, adriamycin, daunorubicin, etoposide, teniposide, imatinib, nilotinib, erlotinib, dactinomycin D and a combination thereof; and when the ABC transporter is ABCC1, the ABC transporter substrate chemotherapeutic drug is selected from the group consisting of the anthracycline, the vinca alkaloid, the epipodophyllotoxin, camptothecin, methotrexate, saquinavir, mitoxantrone, imatinib and a combination thereof.